产品名称

MLN 8237 - Alisertib

产品货号

Axon 2003 CAS [1028486-01-2] MF C27H20ClFN4O4MW 518.92 Purity: 99% Soluble in 0.1N NaOH(aq) and DMSO Description Second generation, orally bioavailable, potent and highly selective aurora A inhibitor References Certificates Categories Extra info DA Sloane et al. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem. Biol. 2010, 5(6), 563-576. G Görgün et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010, 115(25), 5202-5213. M Tomita, N Mori. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro. Cancer Sci. 2010, 101(5), 1204-1211. MG Manfredi et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin. Cancer Res. 2011, 17(24), 7614-7624. Certificate of Analysis Material Safety Data Sheet Cell Cycle Regulation Cell Signaling & Oncology Epigenetics EC 2.7.11.1 Aurora Second generation selective Aurora A inhibitor Chemical name 4-(9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[e]pyrimido[5,4-c]azepin-2-ylamino)-2-methoxybenzoic acid Parent CAS No. [1028486-01-2] Order Size Unit Price Stock 5 mg €105.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

MLN 8237 - Alisertib

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 2003

CAS [1028486-01-2]

MF C27H20ClFN4O4
MW 518.92

Purity: 99%
Soluble in 0.1N NaOH(aq) and DMSO

MLN 8237

Description

Second generation, orally bioavailable, potent and highly selective aurora A inhibitor

DA Sloane et al. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem. Biol. 2010, 5(6), 563-576.

G Görgün et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010, 115(25), 5202-5213.

M Tomita, N Mori. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro. Cancer Sci. 2010, 101(5), 1204-1211.

MG Manfredi et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin. Cancer Res. 2011, 17(24), 7614-7624.

Second generation selective Aurora A inhibitor

Chemical name

4-(9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[e]pyrimido[5,4-c]azepin-2-ylamino)-2-methoxybenzoic acid

Parent CAS No.

[1028486-01-2]

产品资料